PMID- 36114573
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220920
IS  - 2162-3619 (Print)
IS  - 2162-3619 (Electronic)
IS  - 2162-3619 (Linking)
VI  - 11
IP  - 1
DP  - 2022 Sep 16
TI  - Rituximab, lenalidomide and BTK inhibitor as frontline treatment for elderly or 
      unfit patients with diffuse large B-cell lymphoma: a real-world analysis of 
      single center.
PG  - 57
LID - 10.1186/s40164-022-00314-w [doi]
LID - 57
AB  - The combination of rituximab, lenalidomide, and Bruton's tyrosine kinase 
      inhibitor (BTKi) ibrutinib, followed by chemotherapy, has shown high efficacy in 
      patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL) in Smart 
      Start trial. We aimed to evaluate the efficacy, safety of SMART 
      (rituximab + lenalidomide + BTKi) regimen and SMART-START regimen as a first-line 
      treatment in elderly or unfit DLBCL patients. 31 patients were included, 17 used 
      SMART regimen, with median age 82 years, 14 unfit patients received SMART-START 
      regimen. 14/16 (87.5%) patients in SMART group achieved overall response (OR), 
      with 10/16 (62.5%) achieved complete response (CR). 12/13 (92.3%) patients in 
      SMART-START group achieved OR, with 8/13 (61.5%) achieved CR. With a median 
      follow-up of 15.4 (3-29.1) months, median progression-free survival (PFS) and 
      overall survival (OS) have not been reached, 1-year PFS was 81% in SMART group 
      and 84% in SMART-START group. Common grade 3-4 adverse events (AEs) during SMART 
      regimen were neutropenia (8 [25.8%]), infection (6 [19.4%]) and skin rash (3 
      [9.7%]). Our study shows that SMART regimen is an effective and safe therapy for 
      elderly DLBCL patients, and SMART-START regimen can be used in unfit patients who 
      could not tolerate intensive chemotherapy in the onset.
CI  - (c) 2022. The Author(s).
FAU - Zhu, Yanan
AU  - Zhu Y
AD  - Department of Hematology, The First Affiliated Hospital, Zhejiang University 
      School of Medicine, Hangzhou, Zhejiang, People's Republic of China.
AD  - Zhejiang Provincial Key Laboratory of Hematopoietic Malignancy, Zhejiang 
      University, Hangzhou, Zhejiang, People's Republic of China.
AD  - Zhejiang Provincial Clinical Research Center for Hematological Disorders, 
      Hangzhou, Zhejiang, People's Republic of China.
AD  - Zhejiang University Cancer Center, Hangzhou, Zhejiang, People's Republic of 
      China.
FAU - Zhang, Xiang
AU  - Zhang X
AD  - Department of Hematology, The First Affiliated Hospital, Zhejiang University 
      School of Medicine, Hangzhou, Zhejiang, People's Republic of China.
AD  - Zhejiang Provincial Key Laboratory of Hematopoietic Malignancy, Zhejiang 
      University, Hangzhou, Zhejiang, People's Republic of China.
AD  - Zhejiang Provincial Clinical Research Center for Hematological Disorders, 
      Hangzhou, Zhejiang, People's Republic of China.
AD  - Zhejiang University Cancer Center, Hangzhou, Zhejiang, People's Republic of 
      China.
FAU - Wei, Juying
AU  - Wei J
AD  - Department of Hematology, The First Affiliated Hospital, Zhejiang University 
      School of Medicine, Hangzhou, Zhejiang, People's Republic of China.
AD  - Zhejiang Provincial Key Laboratory of Hematopoietic Malignancy, Zhejiang 
      University, Hangzhou, Zhejiang, People's Republic of China.
AD  - Zhejiang Provincial Clinical Research Center for Hematological Disorders, 
      Hangzhou, Zhejiang, People's Republic of China.
AD  - Zhejiang University Cancer Center, Hangzhou, Zhejiang, People's Republic of 
      China.
FAU - Yang, Chunmei
AU  - Yang C
AD  - Department of Hematology, The First Affiliated Hospital, Zhejiang University 
      School of Medicine, Hangzhou, Zhejiang, People's Republic of China.
AD  - Zhejiang Provincial Key Laboratory of Hematopoietic Malignancy, Zhejiang 
      University, Hangzhou, Zhejiang, People's Republic of China.
AD  - Zhejiang Provincial Clinical Research Center for Hematological Disorders, 
      Hangzhou, Zhejiang, People's Republic of China.
AD  - Zhejiang University Cancer Center, Hangzhou, Zhejiang, People's Republic of 
      China.
FAU - Tong, Hongyan
AU  - Tong H
AD  - Department of Hematology, The First Affiliated Hospital, Zhejiang University 
      School of Medicine, Hangzhou, Zhejiang, People's Republic of China.
AD  - Zhejiang Provincial Key Laboratory of Hematopoietic Malignancy, Zhejiang 
      University, Hangzhou, Zhejiang, People's Republic of China.
AD  - Zhejiang Provincial Clinical Research Center for Hematological Disorders, 
      Hangzhou, Zhejiang, People's Republic of China.
AD  - Zhejiang University Cancer Center, Hangzhou, Zhejiang, People's Republic of 
      China.
FAU - Mai, Wenyuan
AU  - Mai W
AD  - Department of Hematology, The First Affiliated Hospital, Zhejiang University 
      School of Medicine, Hangzhou, Zhejiang, People's Republic of China.
AD  - Zhejiang Provincial Key Laboratory of Hematopoietic Malignancy, Zhejiang 
      University, Hangzhou, Zhejiang, People's Republic of China.
AD  - Zhejiang Provincial Clinical Research Center for Hematological Disorders, 
      Hangzhou, Zhejiang, People's Republic of China.
AD  - Zhejiang University Cancer Center, Hangzhou, Zhejiang, People's Republic of 
      China.
FAU - Yang, Min
AU  - Yang M
AD  - Department of Hematology, The First Affiliated Hospital, Zhejiang University 
      School of Medicine, Hangzhou, Zhejiang, People's Republic of China.
AD  - Zhejiang Provincial Key Laboratory of Hematopoietic Malignancy, Zhejiang 
      University, Hangzhou, Zhejiang, People's Republic of China.
AD  - Zhejiang Provincial Clinical Research Center for Hematological Disorders, 
      Hangzhou, Zhejiang, People's Republic of China.
AD  - Zhejiang University Cancer Center, Hangzhou, Zhejiang, People's Republic of 
      China.
FAU - Qian, Jiejing
AU  - Qian J
AD  - Department of Hematology, The First Affiliated Hospital, Zhejiang University 
      School of Medicine, Hangzhou, Zhejiang, People's Republic of China.
AD  - Zhejiang Provincial Key Laboratory of Hematopoietic Malignancy, Zhejiang 
      University, Hangzhou, Zhejiang, People's Republic of China.
AD  - Zhejiang Provincial Clinical Research Center for Hematological Disorders, 
      Hangzhou, Zhejiang, People's Republic of China.
AD  - Zhejiang University Cancer Center, Hangzhou, Zhejiang, People's Republic of 
      China.
FAU - Mao, Liping
AU  - Mao L
AD  - Department of Hematology, The First Affiliated Hospital, Zhejiang University 
      School of Medicine, Hangzhou, Zhejiang, People's Republic of China.
AD  - Zhejiang Provincial Key Laboratory of Hematopoietic Malignancy, Zhejiang 
      University, Hangzhou, Zhejiang, People's Republic of China.
AD  - Zhejiang Provincial Clinical Research Center for Hematological Disorders, 
      Hangzhou, Zhejiang, People's Republic of China.
AD  - Zhejiang University Cancer Center, Hangzhou, Zhejiang, People's Republic of 
      China.
FAU - Meng, Haitao
AU  - Meng H
AD  - Department of Hematology, The First Affiliated Hospital, Zhejiang University 
      School of Medicine, Hangzhou, Zhejiang, People's Republic of China.
AD  - Zhejiang Provincial Key Laboratory of Hematopoietic Malignancy, Zhejiang 
      University, Hangzhou, Zhejiang, People's Republic of China.
AD  - Zhejiang Provincial Clinical Research Center for Hematological Disorders, 
      Hangzhou, Zhejiang, People's Republic of China.
AD  - Zhejiang University Cancer Center, Hangzhou, Zhejiang, People's Republic of 
      China.
FAU - Jin, Jie
AU  - Jin J
AD  - Department of Hematology, The First Affiliated Hospital, Zhejiang University 
      School of Medicine, Hangzhou, Zhejiang, People's Republic of China. 
      jiej0503@zju.edu.cn.
AD  - Zhejiang Provincial Key Laboratory of Hematopoietic Malignancy, Zhejiang 
      University, Hangzhou, Zhejiang, People's Republic of China. jiej0503@zju.edu.cn.
AD  - Zhejiang Provincial Clinical Research Center for Hematological Disorders, 
      Hangzhou, Zhejiang, People's Republic of China. jiej0503@zju.edu.cn.
AD  - Zhejiang University Cancer Center, Hangzhou, Zhejiang, People's Republic of 
      China. jiej0503@zju.edu.cn.
FAU - Yu, Wenjuan
AU  - Yu W
AD  - Department of Hematology, The First Affiliated Hospital, Zhejiang University 
      School of Medicine, Hangzhou, Zhejiang, People's Republic of China. 
      drwjyu1977@zju.edu.cn.
AD  - Zhejiang Provincial Key Laboratory of Hematopoietic Malignancy, Zhejiang 
      University, Hangzhou, Zhejiang, People's Republic of China. 
      drwjyu1977@zju.edu.cn.
AD  - Zhejiang Provincial Clinical Research Center for Hematological Disorders, 
      Hangzhou, Zhejiang, People's Republic of China. drwjyu1977@zju.edu.cn.
AD  - Zhejiang University Cancer Center, Hangzhou, Zhejiang, People's Republic of 
      China. drwjyu1977@zju.edu.cn.
LA  - eng
GR  - JDZX2015115/Research Project for Practice Development of National TCM Clinical 
      Research Bases/
PT  - Letter
DEP - 20220916
PL  - England
TA  - Exp Hematol Oncol
JT  - Experimental hematology & oncology
JID - 101590676
PMC - PMC9479281
COIS- The authors declare that they have no competing interests.
EDAT- 2022/09/17 06:00
MHDA- 2022/09/17 06:01
PMCR- 2022/09/16
CRDT- 2022/09/16 23:47
PHST- 2022/07/04 00:00 [received]
PHST- 2022/09/08 00:00 [accepted]
PHST- 2022/09/16 23:47 [entrez]
PHST- 2022/09/17 06:00 [pubmed]
PHST- 2022/09/17 06:01 [medline]
PHST- 2022/09/16 00:00 [pmc-release]
AID - 10.1186/s40164-022-00314-w [pii]
AID - 314 [pii]
AID - 10.1186/s40164-022-00314-w [doi]
PST - epublish
SO  - Exp Hematol Oncol. 2022 Sep 16;11(1):57. doi: 10.1186/s40164-022-00314-w.